70.49 0.00 (0.00%)
After hours: 4:55PM EST
|Bid||51.43 x 200|
|Ask||76.00 x 200|
|Day's Range||69.53 - 71.54|
|52 Week Range||37.35 - 75.98|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 12, 2018 - Feb 16, 2018|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||89.08|
Live Audio Webcast Will be on December 14, 2017 SAN DIEGO , Dec. 7, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the BMO Capital Markets 2017 Prescriptions for Success ...
- INGREZZA (valbenazine) Capsules Taken Once-daily Improved Tardive Dyskinesia Symptoms in Patients and was Generally Well Tolerated in 52-week Trial - Additional Data Presented from INGREZZA Clinical ...
Data from the Open-label KINECT 4 Phase III Study to be Presented as an Oral Hot Topic SAN DIEGO , Nov. 29, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that new long-term ...
Live Audio Webcast Will be on November 28, 2017 SAN DIEGO , Nov. 21, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the 29th Annual Piper Jaffray Healthcare Conference ...
NEW YORK, Nov. 21, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Nexstar ...
SAN DIEGO, Nov. 20, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX), a biotechnology company focused on neurological and endocrine related disorders, today announced that Matt Abernethy is joining the executive management team as Chief Financial Officer (CFO). "We are very pleased to welcome Matt Abernethy to the Neurocrine team as our Chief Financial Officer," said Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences. Abernethy has nearly 15 years of experience in the financial sector and investor relations with expertise in the healthcare industry. He joins Neurocrine from Zimmer Biomet, where he held various positions over the past nine years including Vice President, Investor Relations and Treasurer and Vice President of Finance for the Americas and Global Product Engines.
SAN DIEGO, Nov. 14, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that the full manuscript of the long-term safety and efficacy data from the blinded KINECT 3 Phase III extension study evaluating INGREZZA® (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD) were published in the Journal of Clinical Psychiatry1. The once-daily 80 mg and 40 mg doses of INGREZZA continued to maintain symptom improvement and were generally well-tolerated over long-term dosing in patients with TD, a condition characterized by uncontrollable, abnormal and repetitive movements of the trunk, extremities and/or face. "We are pleased with the long-term data, which demonstrate the ability of INGREZZA to effectively improve the symptoms of tardive dyskinesia with durable response," said Christopher O'Brien, M.D., Chief Medical Officer of Neurocrine Biosciences.
SAN DIEGO, Nov. 9, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that INGREZZA® (valbenazine) capsules, the first FDA approved product indicated for the treatment of adults with tardive dyskinesia (TD), a condition characterized by uncontrollable, abnormal and repetitive movements of the trunk, extremities and/or face, was awarded the 2017 Pantheon DiNA Award for Outstanding Therapeutic Product by the California Life Sciences Association (CLSA). CLSA is the state's largest and most influential life sciences advocacy and business leadership organization. CLSA will honor this year's winners at the 2017 Pantheon DiNA Awards ceremony on Friday, November 10, at the Marriott Marquis in San Francisco.
Live Audio Webcast Will be on November 16, 2017 SAN DIEGO , Nov. 8, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Jefferies 2017 London Healthcare Conference at 11:20 ...
SAN DIEGO, Nov. 7, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced that data for INGREZZA® (valbenazine) capsules, the first FDA approved treatment for adults with tardive dyskinesia (TD), will be presented at the 2017 Neuroscience Education Institute Congress to be held November 8-12 in Colorado Springs, Colorado. Data being presented include analyses from the RE-KINECT study, a real-world screening study and registry that describes the presence and impact of involuntary movements in patients taking antipsychotics, as well as pooled data analyses from INGREZZA clinical studies across patient sub-groups. "We are pleased to share findings on the impact of tardive dyskinesia, which is characterized by uncontrollable, abnormal and repetitive movements, on real-world patients," said Chris O'Brien, M.D., Chief Medical Officer of Neurocrine.
NEW YORK, NY / ACCESSWIRE / November 3, 2017 / Neurocrine Biosciences was a big mover on Thursday, even hitting a new high after outstanding third quarter results and impressive INGREZZA sales. Alnylam ...
On November 1, 2017, Neurocrine Biosciences, Inc. (NBIX) announced financial results for the third quarter of 2017 and provided a business update. The company reported $45.8 million in revenues from the sale of INGREZZA® for the treatment of tardive dyskinesia (TD), which was way ahead of even the most optimistic expectations. On October 5, 2017, the company announced that the FDA approved the 80 mg capsule of INGREZZA®.
The performance of the tardive dyskinesia drug Ingrezza had sell-side analysts gushing over Neurocrine Biosciences, Inc. (NASDAQ: NBIX )'s third-quarter results . Given the buoyancy surrounding Ingrezza, ...
The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.